Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.

Autor: Esparham A; Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Mehri A; Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Dalili A; Department of General Surgery, School of Medicine, Surgical Oncology Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran., Richards J; Department of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, USA., Khorgami Z; Department of Surgery, University of Oklahoma, School of Community Medicine, Tulsa, Oklahoma, USA.; Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Jazyk: angličtina
Zdroj: Obesity reviews : an official journal of the International Association for the Study of Obesity [Obes Rev] 2024 Nov; Vol. 25 (11), pp. e13811. Date of Electronic Publication: 2024 Aug 12.
DOI: 10.1111/obr.13811
Abstrakt: Introduction: Weight regain and insufficient weight loss are major challenges after metabolic bariatric surgery (MBS), affecting patients' comorbidities and quality of life. The current systematic review and meta-analysis aim to assess the efficacy and safety of GLP-1 receptor agonists (GLP-1 RA) in patients with weight regain or insufficient weight loss after MBS.
Methods: A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases to find the relevant studies.
Results: A total of 19 articles were included. The highest doses of liraglutide and semaglutide were 3 mg per day and 1 mg once weekly, respectively, in the included studies. The mean differences in weight and body mass index after treatment were -7.02 kg or 3.07 kg/m 2 , -8.65 or -5.22 kg/m 2 , and -6.99 kg or -3.09 kg/m 2 for treatment durations of ≤ 6 months, 6-12 months, and >12 months with liraglutide, respectively. Additionally, weekly semaglutide showed significantly greater weight loss compared to daily liraglutide, with a mean difference of 4.15 kg. Common complications included nausea (19.1%), constipation (8.6%), abdominal pain (3.7%), and vomiting (2.4%).
Conclusion: Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.
(© 2024 World Obesity Federation.)
Databáze: MEDLINE
Externí odkaz: